As a multi-targeted tyrosine kinase inhibitor indicated for the treatment of specific cancers, dosage adjustment for special populations must be strictly performed under the guidance of a physician. Its safety and dosage require individualized evaluation based on the patient’s age, hepatic and renal function, pregnancy status, etc. Close monitoring for adverse reactions is necessary during the treatment course.
Administration in Elderly Patients
Organ function may decline in the elderly. Therefore, assessment of hepatic and renal function as well as overall health status is required prior to medication. Dosage adjustment should be determined based on clinical responses and tolerability.
Enhanced monitoring is needed during treatment, particularly for adverse reactions such as hypertension and proteinuria.
Pregnant and Lactating Women
Contraindicated in pregnant women
Anlotinib may have embryotoxic potential. Women of childbearing age must take effective contraceptive measures during the treatment period and for at least 6 months after discontinuation of the drug.
Avoid use during lactation
The drug may be excreted in human milk. Lactating women should either suspend medication or discontinue breastfeeding.
Patients with Hepatic Impairment
Caution is advised when administering anlotinib to patients with moderate to severe hepatic impairment (e.g., Child-Pugh Class B/C), which may require dosage reduction or temporary treatment suspension.
Patients with mild hepatic dysfunction need close monitoring of transaminase and bilirubin levels.
Patients with Renal Impairment
No dosage adjustment is required for patients with mild to moderate renal impairment, but regular monitoring of urinary protein and serum creatinine levels is essential.
Limited clinical data are available for patients with severe renal impairment or those undergoing dialysis; therefore, cautious use is recommended.
Pediatric and Adolescent Patients
Data on the safety and efficacy of anlotinib in individuals under 18 years of age are insufficient. The decision to use the drug must be made by a specialist physician after evaluating the potential benefits against the risks.
Precautions
Use as prescribed: Anlotinib is a prescription-only medication. The specific treatment regimen must be formulated by the physician based on the patient’s condition.
Regular monitoring of blood pressure, coagulation function, urine routine and other indicators is required during treatment. Immediate medical attention should be sought if severe adverse reactions (e.g., hemorrhage, thrombosis) occur.
